Platelet factor 4 binds to bacteria-inducing antibodies cross-reacting with the major antigen in heparin-induced thrombocytopenia

Blood

Volumn 117, Issue 4, 2011, Pages 1370-1378

  Krauel, Krystin ^a   Pötschke, Christian ^a   Weber, Claudia ^b   Kessler, Wolfram ^b   Fürll, Birgitt ^a   Ittermann, Till ^b   Maier, Stefan ^b   Hammerschmidt, Sven ^b   Bröker, Barbara M ^a   Greinacher, Andreas ^a  

^a UNIVERSITY MEDICINE GREIFSWALD   (Germany)

^b UNIVERSITY OF GREIFSWALD   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; THROMBOCYTE FACTOR 4;

ARTICLE; B LYMPHOCYTE; BACTERIAL INFECTION; ESCHERICHIA COLI; HEPARIN INDUCED THROMBOCYTOPENIA; HOST RESISTANCE; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; MOUSE; NONHUMAN; PHAGOCYTOSIS; PRIORITY JOURNAL; STAPHYLOCOCCUS AUREUS;

EID: 79251583424     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2010-08-301424     Document Type: Article

References (50)

1. Harrison P, Cramer EM. Platelet alpha-granules. Blood Rev. 1993;7(1):52-62.
2. Fiore MM, Mackie IM. Mechanism of low-molecular-weight heparin reversal by platelet factor 4. Thromb Res. 2009;124(1):149-155.
3. Mixon TA, Dehmer GJ. Recombinant platelet factor 4 for heparin neutralization. Semin Thromb Hemost. 2004;30(3):369-377. (Pubitemid 39037631)
4. Greinacher A, Potzsch B, Amiral J, Dummel V, Eichner A, Mueller-Eckhardt C. Heparin-associated thrombocytopenia: isolation of the antibody and characterization of a multimolecular PF4-heparin complex as the major antigen. Thromb Haemost. 1994;71(2):247-251.
5. Greinacher A, Gopinadhan M, Gunther JU, et al. Close approximation of two platelet factor 4 tetramers by charge neutralization forms the antigens recognized by HIT antibodies. Arterioscler Thromb Vasc Biol. 2006;26(10):2386-2393.
6. Rauova L, Poncz M, McKenzie SE, et al. Ultralarge complexes of PF4 and heparin are central to the pathogenesis of heparin-induced thrombocytopenia 2. Blood. 2005;105(1):131-138.
7. Warkentin TE, Chong BH, Greinacher A. Heparin-induced thrombocytopenia: towards consensus. Thromb Haemost. 1998;79(1):1-7.
8. Arepally GM, Ortel TL. Clinical practice: heparin-induced thrombocytopenia. N Engl J Med. 2006;355(8):809-817.
9. Greinacher A, Kohlmann T, Strobel U, Sheppard JA, Warkentin TE. The temporal profile of the anti-PF4/heparin immune response. Blood. 2009;113(20):4970-4976.
10. Warkentin TE, Sheppard JA, Moore JC, Cook RJ, Kelton JG. Studies of the immune response in heparin-induced thrombocytopenia. Blood. 2009;113(20):4963- 4969.
11. Greinacher A, Eichler P, Lietz T, Warkentin TE. Replacement of unfractionated heparin by low-molecular-weight heparin for postorthopedic surgery antithrombotic prophylaxis lowers the overall risk of symptomatic thrombosis because of a lower frequency of heparin-induced thrombocytopenia. Blood. 2005;106(8):2921-2922.
12. Pouplard C, May MA, Iochmann S, et al. Antibodies to platelet factor 4-heparin after cardiopulmonary bypass in patients anticoagulated with unfractionated heparin or a low-molecular-weight heparin: clinical implications for heparin-induced thrombocytopenia. Circulation. 1999;99(19):2530-2536.
13. Warkentin TE, Sheppard JA, Horsewood P, Simpson PJ, Moore JC, Kelton JG. Impact of the patient population on the risk for heparin-induced thrombocytopenia. Blood. 2000;96(5):1703-1708. (Pubitemid 30661052)
14. Arepally GM, Hursting MJ. Platelet factor 4/heparin antibody (IgG/M/A) in healthy subjects: a literature analysis of commercial immunoassay results. J Thromb Thrombolysis. 2008;26(1):55-61.
15. Warkentin TE, Sheppard JI, Moore JC, Sigouin CS, Kelton JG. Quantitative interpretation of optical density measurements using PF4-dependent enzyme-immunoassays. J Thromb Haemost. 2008;6(8):1304-1312.
16. Jay RM, Warkentin TE. Fatal heparin-induced thrombocytopenia (HIT) during warfarin thromboprophylaxis following orthopedic surgery: another example of 'spontaneous' HIT? J Thromb Haemost. 2008;6(9):1598-1600.
17. Pruthi RK, Daniels PR, Nambudiri GS, Warkentin TE. Heparin-induced thrombocytopenia (HIT) during postoperative warfarin thromboprophylaxis: a second example of postorthopedic surgery 'spontaneous' HIT. J Thromb Haemost. 2009;7(3):499-501.
18. Warkentin TE, Makris M, Jay RM, Kelton JG. A spontaneous prothrombotic disorder resembling heparin-induced thrombocytopenia. Am J Med. 2008;121(7):632-636.
19. Greinacher A, Michels I, Mueller-Eckhardt C. Heparin-associated thrombocytopenia: the antibody is not heparin specific. Thromb Haemost. 1992;67(5):545-549.
20. Greinacher A, Alban S, Dummel V, Franz G, Mueller-Eckhardt C. Characterization of the structural requirements for a carbohydrate based anticoagulant with a reduced risk of inducing the immunological type of heparin-associated thrombocytopenia. Thromb Haemost. 1995;74(3):886-892.
21. Visentin GP, Moghaddam M, Beery SE, McFarland JG, Aster RH. Heparin is not required for detection of antibodies associated with heparin-induced thrombocytopenia/thrombosis. J Lab Clin Med. 2001;138(1):22-31.
22. Greinacher A, Michels I, Schafer M, Kiefel V, Mueller-Eckhardt C. Heparin-associated thrombocytopenia in a patient treated with polysulphated chondroitin sulphate: evidence for immunological crossreactivity between heparin and polysulphated glycosaminoglycan. Br J Haematol. 1992;81(2):252-254.
23. Beveridge TJ. Structures of gram-negative cell walls and their derived membrane vesicles. J Bacteriol. 1999;181(16):4725-4733.
24. Neuhaus FC, Baddiley J. A continuum of anionic charge: structures and functions of D-alanyl-teichoic acids in gram-positive bacteria. Microbiol Mol Biol Rev. 2003;67(4):686-723.
25. Unkmeir A, Latsch K, Dietrich G, et al. Fibronectin mediates Opc-dependent internalization of Neisseria meningitidis in human brain microvascular endothelial cells. Mol Microbiol. 2002;46(4):933-946.
26. Pracht D, Elm C, Gerber J, et al. PavA of Streptococcus pneumoniae modulates adherence, invasion, and meningeal inflammation. Infect Immun. 2005;73(5):2680-2689.
27. Bubert A, Sokolovic Z, Chun SK, Papatheodorou L, Simm A, Goebel W. Differential expression of Listeria monocytogenes virulence genes in mammalian host cells. Mol Gen Genet. 1999;261(2):323-336. (Pubitemid 29140047)
28. Rennemeier C, Hammerschmidt S, Niemann S, Inamura S, Zahringer U, Kehrel BE. Thrombospondin-1 promotes cellular adherence of gram-positive pathogens via recognition of peptidoglycan. FASEB J. 2007;21(12):3118-3132. (Pubitemid 47565532)
29. Newman PM, Swanson RL, Chong BH. Heparin-induced thrombocytopenia: IgG binding to PF4-heparin complexes in the fluid phase and cross-reactivity with low molecular weight heparin and heparinoid. Thromb Haemost. 1998;80(2):292-297.
30. Krauel K, Furll B, Warkentin TE, et al. Heparin-induced thrombocytopenia: therapeutic concentrations of danaparoid, unlike fondaparinux and direct thrombin inhibitors, inhibit formation of platelet factor 4-heparin complexes. J Thromb Haemost. 2008;6(12):2160-2167.
31. Juhl D, Eichler P, Lubenow N, Strobel U, Wessel A, Greinacher A. Incidence and clinical significance of anti-PF4/heparin antibodies of the IgG, IgM, and IgA class in 755 consecutive patient samples referred for diagnostic testing for heparin-induced thrombocytopenia. Eur J Haematol. 2006;76(5):420-426.
32. Warkentin TE, Greinacher A. Laboratory testing for heparin-induced thrombocytopenia. In: Warkentin TE, Greinacher A, eds. Heparin-induced Thrombocytopenia. New York, NY: Informa Healthcare; 2007:227-238.
33. Kiefel V, Santoso S, Weisheit M, Mueller-Eckhardt C. Monoclonal antibody-specific immobilization of platelet antigens (MAIPA): a new tool for the identification of platelet-reactive antibodies. Blood. 1987;70(6):1722-1726.
34. Maier S, Traeger T, Entleutner M, et al. Cecal ligation and puncture versus colon ascendens stent peritonitis: two distinct animal models for polymicrobial sepsis. Shock. 2004;21(6):505-511.
35. Zantl N, Uebe A, Neumann B, et al. Essential role of gamma interferon in survival of colon ascendens stent peritonitis, a novel murine model of abdominal sepsis. Infect Immun. 1998;66(5):2300-2309.
36. John U, Greiner B, Hensel E, et al. Study of Health In Pomerania (SHIP). A health examination survey in an East German region: objectives and design. Soz Praventivmed. 2001;46(3):186-194.
37. Volzke H, Alte D, Schmidt CO, et al. Cohort profile: the study of health in Pomerania [published online ahead of print, February 18, 2010]. Int J Epidemiol. doi: 10.1093/ije/dyp394.
38. Warkentin TE, Kelton JG. Temporal aspects of heparin-induced thrombocytopenia. N Engl J Med. 2001;344(17):1286-1292.
39. Pouplard C, Amiral J, Borg JY, Vissac AM, Delahousse B, Gruel Y. Differences in specificity of heparin-dependent antibodies developed in heparin-induced thrombocytopenia and consequences on cross-reactivity with danaparoid sodium. Br J Haematol. 1997;99(2):273-280.
40. Sheridan D, Carter C, Kelton JG. A diagnostic test for heparin-induced thrombocytopenia. Blood. 1986;67(1):27-30.
41. Whitlatch NL, Perry SL, Ortel TL. Anti-heparin/platelet factor 4 antibody optical density values and the confirmatory procedure in the diagnosis of heparin-induced thrombocytopenia. Thromb Haemost. 2008;100(4):678-684.
42. Rauova L, Zhai L, Kowalska MA, Arepally GM, Cines DB, Poncz M. Role of platelet surface PF4 antigenic complexes in heparin-induced thrombocytopenia pathogenesis: diagnostic and therapeutic implications. Blood. 2006;107(6):2346-2353.
43. Alban S, Greinacher A. Role of sulfated polysaccharides in the pathogenesis of heparin-induced thrombocytopenia. In: Warkentin TE, Greinacher A, eds. Heparin-induced Thrombocytopenia. New York, NY: Informa Healthcare; 2007:167-186.
44. Warkentin TE, Greinacher A, Koster A, Lincoff AM. Treatment and prevention of heparin-induced thrombocytopenia: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008;133(6)[suppl]:340S-380S.
45. Selleng K, Schutt A, Selleng S, Warkentin TE, Greinacher A. Studies of the anti-platelet factor 4/heparin immune response: adapting the enzyme-linked immunosorbent spot assay for detection of memory B cells against complex antigens. Transfusion. 2010;50(1):32-39.
46. Kowalska MA, Mahmud SA, Lambert MP, Poncz M, Slungaard A. Endogenous platelet factor 4 stimulates activated protein C generation in vivo and improves survival after thrombin or lipopolysaccharide challenge. Blood. 2007;110(6):1903-1905.
47. Reilly MP, Taylor SM, Hartman NK, et al. Heparin-induced thrombocytopenia/thrombosis in a transgenic mouse model requires human platelet factor 4 and platelet activation through FcgammaRIIA. Blood. 2001;98(8):2442-2447.
48. Greinacher A, Michels I, Liebenhoff U, Presek P, Mueller-Eckhardt C. Heparin-associated thrombocytopenia: immune complexes are attached to the platelet membrane by the negative charge of highly sulphated oligosaccharides. Br J Haematol. 1993;84(4):711-716. (Pubitemid 23248066)
49. Horne MK III. Heparin binding to normal and abnormal platelets. Thromb Res. 1988;51(2):135-144.
50. Horne MK III, Chao ES. Heparin binding to resting and activated platelets. Blood. 1989;74(1):238-243.